Despite concerns that recombinant human Activated Protein C (rhAPC) is associated with an increased risk of bleeding, the FDA failed to list several of the bleeding-related exclusion criteria used in the PROWESS trial as contraindications to use of this agent.
Article Limit Reached
You have reached your article limit for the month. Subscribe now to access this article plus other member-only content.
- Award-winning Medical Content
- Latest Advances & Development in Medicine
- Unbiased Content